SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
Ernest NadalJ Bosch-BarreraS CedrésJ CovesR García-CampeloM GuiradoR López-CastroA L OrtegaD VicenteJ de Castro-CarpeñoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)
Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.
Keyphrases
- locally advanced
- early stage
- end stage renal disease
- small cell lung cancer
- healthcare
- squamous cell carcinoma
- chronic kidney disease
- rectal cancer
- newly diagnosed
- randomized controlled trial
- ejection fraction
- stem cells
- radiation therapy
- clinical trial
- heart rate
- advanced non small cell lung cancer
- prognostic factors
- current status
- body composition
- resistance training
- bone marrow
- epidermal growth factor receptor